HC Wainwright keeps USD 361 target for Krystal Biotech stock

Published on 10/20/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HC Wainwright kept its USD 361.00 target on October 15, 2026. Krystal Biotech stock costs EUR 289.80 on October 20, 2026.

Analyst target and reporting date

HC Wainwright reaffirmed its USD 361.00 target and Buy rating on October 15, 2026.
Second-quarter 2026 revenue reached USD 119.22 million, up 24.00 percent year over year.
Krystal Biotech stock traded at EUR 289.80 at Lang & Schwarz on October 20, 2026 at 7:47 p.m. CEST.
MarketBeat estimated third-quarter 2026 results for November 2, 2026.

KRYS, US5011471027, Illustration mit AI erstellt.

Krystal Biotech (ISIN US5011471027) has a USD 361.00 price target from HC Wainwright, which reaffirmed its Buy rating in a report issued on October 15, 2026, according to MarketBeat. The target is 10.84 percent above the USD 325.69 Nasdaq price at the latest quoted session level. Krystal Biotech stock was trading at EUR 289.80 at Lang & Schwarz on October 20, 2026 at 7:47 p.m. CEST.

Revenue growth remains central

Krystal Biotech reported USD 119.22 million of revenue for the second quarter of 2026, up 24.00 percent from USD 96.00 million in the second quarter of 2025. The company also reported USD 54.80 million of net income, or USD 1.79 diluted earnings per share, compared with USD 38.30 million and USD 1.29 in the year-earlier quarter, according to Stock Analysis. The quarter therefore combined higher sales with a 42.64 percent increase in net income.

Stock stays below its yearly high

At USD 325.69 on October 20, 2026 at 1:51 p.m. ET, KRYS stood 14.86 percent below its 52-week high of USD 382.54 and 77.95 percent above its 52-week low of USD 183.03. The same session showed 71,281 shares traded. The USD 9.64 billion market capitalization and a price-to-earnings ratio of 40.81 place the valuation well above the two comparison companies used below, although their negative earnings make direct P/E comparisons unavailable.

What does November 2 mean?

Krystal Biotech is estimated to report third-quarter 2026 results before the market opens on November 2, 2026, with an 8:30 a.m. ET conference call, according to MarketBeat. The published consensus calls for USD 126.77 million of revenue and USD 1.84 earnings per share for the third quarter of 2026, versus USD 97.80 million and USD 2.66 in the third quarter of 2025. That implies 29.62 percent revenue growth but a 30.83 percent decline in expected earnings per share.

Comparison with peers

Krystal Biotech: up 1.70 percent on Nasdaq, P/E 40.81, market capitalization USD 9.6 billion.

Sarepta Therapeutics: up 9.39 percent on Nasdaq, market capitalization USD 2.0 billion.

Ultragenyx Pharmaceutical: up 7.37 percent on Nasdaq, market capitalization USD 1.6 billion.

Price remains the frame

The analyst target, the upcoming reporting date and the second-quarter revenue increase give investors three measurable reference points. The next earnings release will test whether the expected USD 126.77 million revenue level can extend the 24.00 percent year-over-year growth reported for the second quarter.

Krystal Biotech was trading at EUR 289.80 at Lang & Schwarz on October 20, 2026 at 7:47 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Krystal Biotech stock.